Search results
FDA signals potential shift toward interchangeability for all biosimilars | JD Supra
JD Supra· 2 days agoUnder the Biologics Price Competition and Innovation Act (BPCIA), a “biosimilar” product is one that is demonstrated to be “highly similar” to the reference product with “no clinically meaningful ...